REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
17/08/2018 13:15
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180816:nRSP1896Ya
RNS Number : 1896Y
Morgan Stanley
17 August 2018
AMENDMENT Section (2a & 3a)
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR
WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form Takeda Pharmaceutical Company Limited
relates:
Use a separate form for each offeror/offeree
(c) Name of the party to the offer with which exempt principal trader is Shire plc
connected:
(d) Date position held/dealing undertaken: 15 AUGUST 2018
For an opening position disclosure, state the latest practicable date
prior to the disclosure
(e) In addition to the company in 1(b) above, is the exempt principal trader YES - Shire plc
making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. POSITIONS OF THE EXEMPT PRINCIPAL
TRADER
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(b), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing
(if any)
Class of relevant security: Ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 6,342,289 0.81 12,199,644 1.54
(2) Cash-settled derivatives: 11,737,765 1.50 5,840,308 0.74
(3) Stock-settled derivatives (including options) and agreements to 0 0.00 0 0.00
purchase/sell:
18,080,054 2.31 18,039,952 2.28
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors'
and other employee options)
Class of relevant security in relation to which subscription right exists: N/A
Details, including nature of the rights concerned and relevant percentages: N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchases/sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary PURCHASES 1,062,402 4,606.0000 JPY 4,534.0000 JPY
Ordinary SALES 1,001,801 4,607.0000 JPY 4,535.0000 JPY
(b) Cash-settled derivative transactions
Class of relevant security Product description Nature of dealing Number of reference securities Price per unit
e.g. CFD e.g. opening/closing a long/short position, increasing/reducing a long/short
position
Ordinary CFD SHORT 24100 4552.2116 JPY
Ordinary CFD LONG 1800 4578.7777 JPY
Ordinary CFD SHORT 100 4586.0000 JPY
Ordinary CFD SHORT 200 4543.5000 JPY
Ordinary CFD SHORT 3300 4551.5757 JPY
Ordinary CFD LONG 2100 4577.9047 JPY
Ordinary CFD SHORT 600 4540.0000 JPY
Ordinary CFD SHORT 7300 4553.6712 JPY
Ordinary CFD LONG 100 4562.0000 JPY
Ordinary CFD SHORT 100 4580.0000 JPY
Ordinary CFD LONG 100 4586.0000 JPY
Ordinary CFD LONG 1800 4586.0000 JPY
Ordinary CFD SHORT 1300 4552.3076 JPY
Ordinary CFD SHORT 600 4547.8333 JPY
Ordinary CFD SHORT 12300 4553.5318 JPY
Ordinary CFD SHORT 64100 4558.2979 JPY
Ordinary CFD LONG 1600 4558.9375 JPY
Ordinary CFD LONG 1000 4580.0000 JPY
Ordinary CFD SHORT 1000 4540.0000 JPY
Ordinary CFD LONG 2800 4575.6071 JPY
Ordinary CFD SHORT 800 4546.8750 JPY
Ordinary CFD SHORT 7700 4558.9350 JPY
Ordinary CFD SHORT 200 4569.5000 JPY
Ordinary CFD SHORT 1000 4540.0000 JPY
Ordinary CFD LONG 1000 4580.0000 JPY
Ordinary CFD LONG 35300 4581.3824 JPY
Ordinary CFD LONG 400 4539.7500 JPY
Ordinary CFD SHORT 100 4580.0000 JPY
Ordinary CFD SHORT 36600 4553.9480 JPY
Ordinary CFD LONG 100 4538.0000 JPY
Ordinary CFD SHORT 11000 4540.0000 JPY
Ordinary CFD SHORT 11000 4540.0000 JPY
Ordinary CFD LONG 11000 4540.0000 JPY
Ordinary CFD LONG 700 4569.2857 JPY
Ordinary CFD SHORT 400 4573.2500 JPY
Ordinary CFD SHORT 543400 4540.0479 JPY
Ordinary CFD LONG 601500 4551.7144 JPY
Ordinary CFD LONG 19500 4576.8256 JPY
Ordinary CFD SHORT 113551 4571.1400 JPY
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type Expiry date Option money paid/ received per unit
e.g. American, European etc.
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit
e.g. call option
N/A N/A N/A N/A N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
N/A N/A N/A N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the exempt
principal trader making the disclosure and any party to the offer or any
person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If
there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the exempt principal trader making the disclosure and any other person
relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 17 AUGUST 2018
Contact name: Craig Horsley
Telephone number: +44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service and must also be emailed to the Takeover Panel at
monitoring@disclosure.org.uk (mailto:monitoring@disclosure.org.uk) . The
Panel's Market Surveillance Unit is available for consultation in relation to
the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement